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Context: Antenatal corticosteroids commonly are administered to pregnant women at risk of 
delivering between 23 and 34 gestational weeks, providing crucial benefits to fetal lung 
maturation and reducing risk of neonatal morbidity and mortality. Corticosteroids are maximally 
efficacious for lung maturation when administered within 2 to 7 days of delivery. Accurately 
identifying the timing of preterm delivery is thus critical to ensure that antenatal corticosteroids 
are administered within a week of delivery and to avoid unnecessary administration to women 
who will deliver at term. A plausible biomarker for predicting time of delivery is placental 
corticotropin-releasing hormone (pCRH). Objective: The current study assesses whether pCRH 
concentrations predict time to delivery, and specifically which women will deliver within a week 
of treatment. Design: pCRH concentrations were evaluated prior to administration of the 
corticosteroid betamethasone and timing of delivery was recorded. Participants: 121 women 
with singleton pregnancies who were prescribed betamethasone. Results: Elevated pCRH 
concentrations were associated with a shorter time from treatment to delivery. ROC curves 
revealed that pCRH may improve the precision of predicting preterm delivery. Conclusions: In 
the current sample, pCRH concentrations predicted the likelihood of delivering within one week 
of corticosteroid treatment. Current findings suggest that pCRH may be a diagnostic indicator of 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-00956/5094018 by C
hapm
an U
niversity Library user on 17 Septem
ber 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00956 
 
 
2
impending preterm delivery. Increasing the precision in predicting time to delivery could inform 
when to administer antenatal corticosteroids, thus maximizing benefits and reducing the 
likelihood of exposing fetuses who will be delivered at term. 
Placental corticotropin-releasing hormone predicts impending delivery (i.e., delivery within a week) among 
pregnant women at risk for preterm birth. 
1. Introduction 
Preterm birth (i.e. delivery prior to 37 weeks gestation) is one of the leading causes of perinatal 
morbidity and mortality, as 12-13% of women deliver preterm each year within the United 
States. [1] Infants born preterm are at heightened risk for respiratory distress syndrome and other 
birth complications. The administration of corticosteroids to women at risk of preterm delivery 
has been the frontline of treatment to promote fetal lung maturation and ultimately decrease 
morbidity and mortality among preterm infants. [2] According to guidelines established by the 
American College of Obstetricians and Gynecologists (ACOG), corticosteroid treatment is 
efficacious for fetal lung maturation when administered antenatally to women who will deliver 
between 24 0/7 and 33 6/7 weeks, [2,3] with recent data indicating a benefit through 36 6/7 
weeks. [4] The benefits of antenatal corticosteroids are maximized when delivery occurs 2 to 7 
days after the initial dose, with respiratory benefits dissipating after 7 days. [3,5] Corticosteroid 
treatment also is associated with reductions in neonatal mortality when delivery occurs within 24 
hours of administration; [5] thus, treatment is recommended when women are at risk of 
delivering within 1 week. [2] There are clear benefits of treatment for infants born preterm, 
including reduced risk of respiratory distress syndrome, intraventricular hemorrhage, morbidity, 
and mortality. [3,6] However in addition to these benefits, antenatal corticosteroids may have 
long-term adverse developmental consequences, [7,8] especially for infants who were at risk for 
preterm birth but proceeded to be delivered at term. Although negative effects of antenatal 
corticosteroids have not been observed in all studies, [2,8-10] administration of corticosteroids 
has been associated with fetal growth restriction, altered brain development, increased emotional 
reactivity, and persisting differences in stress physiology and hypothalamic-pituitary adrenal 
(HPA) axis dysregulation in human [7,8,22-27] and animal studies. [12-21] 
Accurately identifying the risk for impending preterm delivery (i.e., delivery within a week) 
is critical for two reasons: first, to ensure that the timing of antenatal corticosteroid 
administration maximizes benefit to the fetus; and second, to avoid administering corticosteroids 
to women who will go on to deliver at term. As argued by Kamath-Rayne and colleagues, [28] 
improvement in prediction of the timing of preterm birth is needed so that administration of 
antenatal corticosteroids can occur within the ideal time frame of one week prior to delivery. We 
propose that placental corticotropin-releasing hormone (pCRH), a peptide postulated to lie on the 
pathway to preterm birth, could inform the timing of antenatal corticosteroid treatment. [29] 
CRH, a 41-amino-acid neuropeptide, is synthesized primarily in the paraventricular nucleus 
(PVN) of the hypothalamus and has a central role in regulating pituitary and adrenal function and 
the physiological response to stress. [30-32] During pregnancy, CRH also is synthesized and 
released from the placenta (pCRH) and increases dramatically across the course of pregnancy, 
rising 25-fold through 31 weeks of gestation. [32-34] Placental CRH is identical in structure and 
activity to hypothalamic CRH. Concentrations of CRH in maternal circulation are almost 
exclusively of placental origin, because the quantity of hypothalamic CRH in maternal 
circulation is minute and rapidly degrades. [35,36] In the mother, pCRH binds to receptors in the 
pituitary and the adrenal glands, promoting the production of cortisol and 
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dehydroepiandrosterone sulfate (DHEAS) and further release of pCRH from the placenta. 
Placental CRH also binds to receptors in the myometrium, stimulating contractile and relaxatory 
mechanisms. [30,35,37,38] In addition to effects on the mother, pCRH is released into the fetal 
compartment, binding to receptors in the pituitary and fetal zone of the adrenal, promoting the 
synthesis of cortisol and maturation of fetal lungs. Maturation of the fetal lungs is associated 
with increases in surfactant protein A, which may stimulate myometrial contraction. The increase 
of pCRH especially over the latter part of gestation, may therefore act upon various mechanisms 
to promote the onset of labor. Placental CRH has thus been implicated in the pathways 
underlying the timing of parturition. [29,39] 
Prior work has established that pCRH predicts preterm birth in both low risk pregnancies, 
[29,35,39-40] as well as pregnancies at high risk for preterm delivery. [41] However, only two 
known studies have explored whether pCRH can predict delivery within days of assessment 
(e.g., 24 or 48 hours). [42,43] Korebrits and colleagues [42] report that elevated pCRH levels 
predict delivery within 24 hours; and Hill and colleagues [43] report that after 28 gestational 
weeks, elevated pCRH predicts delivery within 48 hours. Research, however, is needed to 
evaluate whether pCRH concentrations assessed prior to antenatal corticosteroid administration 
can inform the timing of treatment within the optimal window (i.e., whether delivery will occur 
within a week). 
The current study evaluates whether pCRH concentrations prior to corticosteroid treatment 
can identify women at risk for impending preterm delivery (i.e., delivery within a week). We 
assess the specificity and sensitivity of pCRH in predicting timing of delivery among pregnant 
women prescribed betamethasone, the most commonly used antenatal corticosteroid. [44] 
2. Subjects and Methods 
A. Study Overview 
We recruited women at risk for preterm delivery who were prescribed betamethasone between 
23 0/7 and 34 0/7 gestational weeks. Placental CRH levels were evaluated prior to 
betamethasone administration, and date of delivery was determined via medical record 
abstraction. Study protocols were reviewed and received approval from the Institutional Review 
Board. Written and informed consent was obtained from the mother before study enrollment. 
B. Participants 
Participants included 121 women at risk for preterm delivery with singleton pregnancies who 
were prescribed betamethasone, from the University of California, Irvine Medical Center 
(UCIMC). Exclusion criteria included: a known HPA axis or endocrine disorder, self-reported 
maternal substance use, prior corticosteroid exposure during this pregnancy, in vitro fertilization, 
and major fetal or chromosomal anomalies. During the recruitment period (from 2011 to 2014), 
43.8% of those women treated with betamethasone failed to meet eligibility criteria and were not 
recruited. Among the eligible women who were approached for participation 18.8% declined due 
to various reasons, the most common of which were: study burden, feeling overwhelmed and 
pregnancy-related worries. 
The decision to administer betamethasone rested entirely on the clinical judgment of the 
attending obstetrician and was made independent of study participation. As per standardized 
hospital protocol, the attending obstetrician evaluated preterm labor at less than 34 weeks, 
administered temporizing measures such as parenteral magnesium sulfate or oral nifedipine, and 
determined whether betamethasone treatment was needed. If deemed necessary, betamethasone 
was administered in 2 doses (12 mg intramuscular, 24 hours apart). Consistent with standard of 
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care, the first dose of betamethasone was given to participants between 23 and 34 weeks’ 
gestation (M = 28.4, SD = 0.3 weeks). On average, delivery occurred 42 days after the first dose 
of betamethasone administration (SD = 31.0 days, Range [0-104]). 
C. Placental CRH assessment 
Maternal blood samples were collected for placental CRH, on average, 36 minutes prior to 
betamethasone treatment (Range [1min to 4hrs 16min]). 50 µL of protease inhibitor, Aprotinin 
(Thermo Fisher Scientific) were added to the plasma tubes and refrigerated. After 30 minutes, 
tubes were centrifuged, processed, and frozen at -70°C. Plasma pCRH assays were completed by 
Dr. Roger Smith's lab at the University of Newcastle, Australia. Placental CRH concentrations 
(pg/ml) were analyzed by radioimmunoassay (RIA) as previously described. [29] Extraction 
recovery was 82.5%. No correction of the data for extraction recoveries was made. Inter- and 
intra-assay coefficients of variance were 9.8% and 7.6% respectively. Data reduction for the RIA 
assay was with a computer assisted logistics program. 
Analyses were performed both with raw pCRH data and with log transformed data, due to 
skewness. Statistical significance was maintained whether untransformed or transformed data 
were used. Raw data are thus presented here in nanomoles per liter (nmol/L) to improve 
interpretability. 
D. Sociodemographic and medical characteristics 
Sociodemographic characteristics including marital and cohabitation status, education, and 
household income were determined at the time of study entry by maternal interview. Family 
income was assessed based on an income-to-needs ratio, calculated by dividing total household 
income by the poverty threshold at the time of assessment, specified by the U.S. Census Bureau.   
Medical records were reviewed to determine obstetric and neonatal medical characteristics. 
Body mass index (BMI) was calculated based on maternal height and weight in the third 
trimester, or within one month of delivery if the mother delivered prior to the third trimester 
(BMI = (height/weight)2). Primary reason for betamethasone treatment was grouped into three 
categories: inflammation, placental issues, and utero-placental insufficiency. The inflammation 
group included women with preterm labor, short cervix, preterm premature rupture of 
membranes (PPROM), chorioamnionitis, or a positive fetal fibronectin test. The placental issues 
group included women with placenta previa, abruption, accreta, or oligohydramnios. The utero-
placental insufficiency group included women with pre-eclampsia, chronic hypertension, 
gestational hypertension, pregnancy-induced hypertension, intrauterine growth restriction, or 
abnormal end diastolic flow results from umbilical artery Doppler velocimetry.  
E. Data Analyses 
As expected, pCRH concentrations were positively correlated with gestational age (GA) at time 
of assessment
 
(r = 0.65, P < 0.001). [38] Thus, all analyses with pCRH covaried with GA at time 
of assessment. The following variables were evaluated as potential covariates and were included 
in the models if they were significantly associated (P < 0.10) with both predictor (pCRH) and 
outcome (time from betamethasone administration to delivery) after adjusting for GA at 
assessment: maternal age, cohabitation, ethnicity, education level, income-to-needs ratio, living 
below the federal poverty line, pregnancy history, and late pregnancy BMI. None of these 
additional variables met criterion for inclusion as a covariate. 
We first used partial correlations in IBM SPSS Statistics for Windows, version 23 (IBM 
Corp., Armonk, N.Y., USA) to evaluate whether pCRH concentrations were associated with time 
from treatment to delivery and gestational age at birth (GAB). Linear regression was employed 
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using SPSS as well to evaluate whether the reason for betamethasone administration accounted 
for study findings (i.e. reason for betamethasone was included as a covariate in a linear 
regression model with pCRH concentrations as the predictor and time from treatment to delivery 
as the outcome variable) or moderated the association between pCRH and time from treatment to 
delivery (i.e. an interaction term was created between reason for betamethasone treatment and 
pCRH concentrations, which was then added to the linear regression model). Next, Cox 
proportional hazard models were fitted to investigate whether pCRH concentrations predicted 
risk for delivering over time. Cox proportional hazard models were performed using SAS 
software for Unix (SAS Institute Inc., Cary, NC, USA). Guidelines from ACOG during the study 
period recommend that corticosteroids be administered to pregnant women between 24 0/7 and 
33 6/7 weeks of gestation, who are at risk of delivering within a week. [2] Thus, the sample was 
divided into two groups: women who delivered within a week of treatment (n = 25) and those 
who delivered after a week (n = 96). Computed receiver operating characteristic (ROC) curves 
assessed the sensitivity and specificity of pCRH concentrations in predicting whether or not 
women would deliver within a week. These models were performed using SAS software. The 
Youden index (sensitivity + [specificity−1]) was computed to obtain a cutoff score that optimizes 
differentiating ability when equal weight is given to sensitivity and specificity. Since optimizing 
sensitivity is a priority for clinical practice, we also identified an alternative cutoff that weighed 
sensitivity over specificity. 
3. Results 
A. Sample Characteristics 
Demographic characteristics of study participants are summarized in Table 1. Women were, on 
average, 30 years of age at recruitment (SD = 6.6; Range [18-46 years]), primarily Latina 
(63.6%), and the majority were cohabitating with a partner (81%). The range of the income-to-
needs ratio was 0 to 33.19. Approximately 1 in 3 participants were living below the federal 
poverty line (income-to-needs ratio below 1.00). 
B. Time from Treatment to Delivery 
All 121 women were prescribed betamethasone at the independent discretion of the attending 
physician and in adherence with current ACOG guidelines. Risk status was thus determined 
entirely by the physician and not in relation to the current study protocol. Of these women, 25 
(20.7%) delivered within a week of treatment. Additionally, 69 (57%) women went on to deliver 
preterm and 52 (43%) delivered at term (see Table 2).  
C. Corticotropin-Releasing Hormone 
Women with elevated pCRH concentrations were more likely to delivery earlier (r = -0.35, P < 
0.001) and were more likely to have a shorter time between treatment and delivery (r = -0.35, P 
< 0.001); see supplemental figures S1A and S1B in the online data repository for correlation 
plots. [45] Further, pCRH concentrations were higher among women who subsequently 
delivered preterm (M = 86.87, SD = 127.34) as compared to women who delivered full term (M 
= 47.28, SD = 43.90; F = 9.51, P = 0.003). Placental CRH concentrations were also higher 
among women who delivered within the week (M = 170.89 pmol/L, SD = 178.45) in as 
compared to those who did not (M = 44.86 pmol/L, SD = 46.70; F = 42.13, P < 0.001). For the 
subset of women who remained pregnant at least a week after treatment, pCRH showed the 
expected increase with advancing gestation (t(89) = -6.194, P < 0.001). However, pCRH levels 
were highly correlated across this one-week period (r = 0.971, P < 0.001).  
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Reason for betamethasone administration (i.e., inflammation, placental issues, utero-
placental insufficiency) did not account for study findings, as pCRH was still a significant 
predictor of time from treatment to delivery after covarying reason for betamethasone 
administration (t (117) = -1.32, P = 0.189). Further, reason for betamethasone administration did 
not moderate the association between pCRH concentrations and time from treatment to delivery 
(β = -0.335, P > 0.250).  
Cox hazard modeling revealed that higher concentrations of pCRH were associated with 
earlier delivery (β = 0.0058, SE = 0.001, P < 0.0001, 95% CI = 0.0036 - 0.0079). Data were 
analyzed continuously, however for illustrative purposes are presented as the top and bottom 
quartiles of pCRH concentrations in Figure 1. For every increase of 10pmol/L of pCRH, the risk 
of delivery (i.e., delivery within a week) was 5.8% higher. 
ROC curves reveal that pCRH concentrations may improve the precision of predicting 
preterm delivery, among a sample of women who received betamethasone under current standard 
of care (area under the curve (AUC) = 0.79, 95% CI = 0.68-0.90, P = 0.001; Figure 2A). The 
ROC model was used to determine optimal pCRH level cutoffs for these data, to predict which 
women were likely to deliver within a week. When specificity was weighted equally with 
sensitivity (maximizing the Youden index), the optimal cutoff score for pCRH for this sample 
with this assay was 72.8 pmol/L (Youden index = 0.52). At this cutoff, 72% of women in this 
sample who delivered within one week would have been correctly identified (sensitivity), 
whereas 20% of women who delivered after one week would have been falsely identified (1-
specificity). See Figure S2A in the online data repository for Kaplan-Meier plots showing the 
probability of remaining pregnant for women with pCRH concentrations above and below the 
Youden index cut-off.  
However, providing betamethasone to women who will deliver within a week (sensitivity) is 
a priority for clinical care and available tools to predict preterm birth are limited. Therefore, to 
prioritize sensitivity while maintaining a reasonable degree of specificity, we identified an 
alternative cutoff value of 15.5 pmol/L for this sample. At this cutoff, 96% of women who 
delivered within one week would have been correctly identified as delivering within this window 
(sensitivity), whereas 69% of women who delivered after one week would have been falsely 
identified (1-specificity). Additionally, if a pCRH cutoff of 15.5 pmol/L were applied to the 
current study sample, 30 women who delivered more than a week after betamethasone 
administration would have avoided unnecessary exposure, 14 of whom delivered at term 
gestation. See Figure S2B in the online data repository for Kaplan-Meier plots showing the 
probability of remaining pregnant for women with pCRH concentrations above and below the 
alternative cut-off.  
4. Discussion 
Our study findings suggest that pCRH concentrations prior to betamethasone treatment predict 
impending preterm delivery. Specifically, among women admitted to the hospital for threatened 
preterm labor and given corticosteroids, elevated pCRH concentrations prior to treatment 
improved discrimination between women who would deliver within a week and those who 
would not. The critical importance of this issue is highlighted by the fact that 43% of women in 
our sample delivered at term gestation. Because of challenges predicting timing of delivery, there 
has been a call for new tools and biomarkers to identify optimal timing of antenatal 
corticosteroid administration. [28] The present findings indicate that pCRH could be an 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-00956/5094018 by C
hapm
an U
niversity Library user on 17 Septem
ber 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00956 
 
 
7
additional tool that contributes to the determination of risk for impending preterm delivery and 
thus, informs timing of corticosteroid administration. 
Decades of research have established that antenatal corticosteroids are a lifesaving treatment 
for preterm infants. [2,5,46] Antenatal corticosteroids provide multiple benefits to fetal health 
and development by stimulating fetal maturation and reducing risk of neonatal morbidity and 
mortality. [2,5,46] The benefits of antenatal corticosteroids are greatest when the infant is 
delivered within 7 days following treatment. [3,5] However, exposure to corticosteroids may be 
associated with elevated risk for neurodevelopmental delays, [7,8,22-27] especially in cases 
where the infant was at risk for preterm delivery but delivered at term. 
Because of the challenges of predicting length of gestation and preterm birth, [28] further 
investigation into biological measures predicting the onset of parturition is needed. Pretreatment 
levels of pCRH show promise in addressing this clinical need, because they predict preterm birth 
and play an integral role in the causal pathways of parturition. [39] Specifically, our findings 
suggest that pCRH may improve our ability to identify women who will go on to deliver within a 
week, so that infants born preterm receive maximum benefit from corticosteroid treatment and 
infants born term avoid unnecessary exposure. In the current sample, a cutoff of 15.5 pmol/L 
correctly identified 96% of women who delivered within a week, with a rate of misclassification 
of 69%. Notably, based on current standard of care, all women within this sample were 
administered corticosteroids, although 79% did not deliver within a week of treatment. Using the 
pCRH cutoff of 15.5 pmol/L, 31% of currently treated women would have been appropriately 
identified as not benefiting from treatment at this time. Findings highlight the potential clinical 
utility of pCRH in identifying if and when offspring may benefit from treatment. 
The possible utility of pCRH as a clinical indicator of impending preterm delivery is 
supported by evidence that pCRH is part of the causal pathway controlling length of gestation. 
[29] Placental CRH concentrations increase dramatically over the course of pregnancy. [39] 
Placental CRH binds to receptors promoting myometrial relaxation; however, as the pregnancy 
progresses, these receptors become less effective and ultimately activate contractile pathways. 
[30] Because of the robust association between pCRH and timing of delivery, pCRH has been 
characterized as part of a “placental clock” controlling the onset of parturition. [31,39] 
To our knowledge, only two studies have used pCRH to prospectively predict delivery within 
a set time frame (e.g., 24 and 48 hours). [42,43] These studies suggest that pCRH after 28 weeks’ 
gestation predicts delivery within 24 to 48 hours. [42,43] The present results extend these 
findings by suggesting that pCRH is a useful biomarker that can aid the decision of whether to 
administer corticosteroids by identifying women who will deliver in less than a week. 
          Although findings suggest that pCRH could potentially serve as a diagnostic 
indicator of impending preterm delivery, several limitations should be addressed. First, 
validation studies with larger samples sizes and across varying populations (e.g. in low risk 
pregnancies) are needed in order to replicate the findings of this single-site investigation and to 
evaluate clinical utility. Second, in our sample, the indications for corticosteroid administration 
were heterogeneous and we did not find that the reason for treatment moderated the relation 
between pCRH and time from treatment to delivery. A strength of this approach is that it 
increases generalizability of our findings to a more medically diverse population of women; 
however, future studies should carefully evaluate these and other clinical risk factors in study 
design and interpretation of findings. Third, the current study recruited women with singleton 
pregnancies. The relevance to multifetal pregnancies thus remains unknown. Fourth, it is also 
unclear if pCRH could be combined with other clinical indicators of preterm birth, including 
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biomarkers such as placental alpha microglobulin-1 (PAMG-1), fetal fibronectin, and 
transvaginal cervical length measurements, to optimize the ability to predict gestational length. 
Exploration of the possible advantages of utilizing multiple indicators of risk for preterm birth 
could further improve accuracy in predicting preterm delivery. 
The findings of this study could have important implications for obstetric practice. If these 
results are replicated work could be done to develop a cost-effective and clinically feasible 
pCRH screen and evaluate its clinical utility in obstetric practice. Enzyme-linked immunosorbent 
assays (ELISAs) have been developed for assessing CRH and future work could explore the 
feasibility of this method as a faster and more cost-effective approach. [47] Placental CRH taps 
in to the causal pathways of delivery, which makes it a promising biomarker for predicting 
impending preterm delivery. More effective clinical tools to predict the timing of parturition 
could guide when to administer corticosteroids and increase the likelihood of providing treatment 
within the optimal time frame of one week prior to preterm delivery. This would maximize 
benefits to preterm neonates, improving lung maturation and reducing rates of mortality and 
respiratory distress syndrome. Further, more precise prediction of timing of delivery would 
reduce the likelihood of administering antenatal corticosteroids to women who will go on to 
deliver at term, and thus whose offspring will not benefit from treatment. A current clinical goal 
is to optimize the sensitivity and specificity of clinical indicators of impending preterm delivery. 
[2,28] pCRH may be a promising biomarker to inform the timing of antenatal corticosteroid 
treatment, which would maximize the likelihood of delivering treatment within the optimal 
window. 
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Figure 1 pCRH concentrations prior to betamethasone treatment predict time to birth. Figure 
Legend The Kaplan-Meier plot reports the probability of remaining pregnant, based on pCRH 
concentrations prior to betamethasone administration. Although all analyses were run 
continuously, for illustrative purposes we present the top and bottom quartiles of pCRH 
concentrations (top quartile in red, bottom quartile in blue). Women with the highest pCRH 
concentrations (top quartile, 82.60 pmol/L) were more likely to deliver sooner, whereas women 
with the lowest pCRH concentrations (bottom quartile, 14.58 pmol/L) were more likely to 
remain pregnant.  
Figure 2 Receiver operating characteristic (ROC) curve (A) and sensitivity and specificity at 
each possible cutoff point (B) for placental corticotropin-releasing hormone (pCRH) at time of 
betamethasone treatment. Figure Legend Sensitivity indicates the probability that a case is 
correctly identified (true positive), and 1-specificity is the probability that a woman who will not 
deliver within 7 days is falsely identified (false positive). 
Table 1. Maternal demographic and medical characteristics 
 Participants, n = 121 
Age at enrollment (yr) 30.2 (6.6) [18.6, 46.9] 
Parity (% Primiparous) 29 (24.0%) 
Ethnicity   
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12 
     Non-Latina White 27 (22.3%) 
     Latina 77 (63.6%) 
     Other 17 (14.0%) 
Gestational Age at Assessment (wks) 28.4 (3.2) [23.0, 33.9] 
Body Mass Index (kg/m2) a 31.3 (0.6) [19.1, 46.5] 
Married or cohabitating 98 (81.0%) 
Years of education 13.37 (2.89) [2.00, 21.00] 
Income to Needs Ratio b   
     <1 36 (32.4%) 
     1-2 33 (29.7%) 
     2-4 17 (15.3%) 
     >4 25 (22.5%) 
Indication for Betamethasone Treatment   
    Placental abnormalities 27 (22.3%) 
    Inflammation 77 (63.6%) 
    Utero-placental insufficiency 17 (14.0%) 
Obstetric risk factors  
    Preeclampsia 11 (9.1%) 
    HELLP 1 (0.8%) 
    Preterm premature rupture of membranes (PPROM) 27 (22.3%) 
    Gestational diabetes 14 (11.6%) 
Diabetes  6 (5.0%) 
pCRH (pmol/L) 69.9 (102.0) [0.25, 600.0] 
Notes: 
Mean (SD) [Range] are presented for continuous variables, and N (%) are presented for categorical variables. 
aBMI is missing 4 participants. 
 bINR is missing 10 participants. 
Table 2. Neonatal medical characteristics 
 Participants, n = 121 
Gestational Age at Birth (weeks) 34.3 (4.7) [24.3, 40.7] 
Preterm (< 37 weeks) 69 (57.0) 
Birth weight (g) 2336.20 (1008.33) [570, 4480] 
Apgar score at 5min a 8.00 [1, 10] 
Sex (% Male) 69 (57.0%) 
Notes: Mean (SD) [Range] are presented for continuous variables, and N (%) are presented for categorical variables. 
a Apgar score is presented as Median [Range]. 
Abbreviations: ACOG, American College of Obstetricians and Gynecologists; AUC, area under the curve; BMI, 
body mass index; GAB, gestational age at birth; pCRH, placental corticotropin-releasing hormone; RIA, 
radioimmunoassay; ROC, receiver operating characteristics. 
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